These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31178490)

  • 21. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
    Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.
    Habu Y; Maeda K; Kusuda T; Yoshino T; Shio S; Yamazaki M; Hayakumo T; Hayashi K; Watanabe Y; Kawai K
    J Gastroenterol; 2005 Nov; 40(11):1029-35. PubMed ID: 16322946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.
    Hoshino S; Kawami N; Takenouchi N; Umezawa M; Hanada Y; Hoshikawa Y; Kawagoe T; Sano H; Hoshihara Y; Nomura T; Iwakiri K
    Digestion; 2017; 95(2):156-161. PubMed ID: 28190016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
    Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
    J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.
    Niikura R; Yamada A; Hirata Y; Hayakawa Y; Takahashi A; Shinozaki T; Takeuchi Y; Fujishiro M; Koike K
    Intern Med; 2018 Sep; 57(17):2443-2450. PubMed ID: 29607951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
    Habu Y; Yoshino T; Shio S; Hayakumo T; Kawai K
    Nihon Rinsho; 2004 Aug; 62(8):1504-9. PubMed ID: 15344541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.
    Shinozaki S; Osawa H; Hayashi Y; Sakamoto H; Miura Y; Lefor AK; Yamamoto H
    Kaohsiung J Med Sci; 2017 Dec; 33(12):616-622. PubMed ID: 29132551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.
    Tanabe T; Hoshino S; Kawami N; Hoshikawa Y; Hanada Y; Takenouchi N; Goto O; Kaise M; Iwakiri K
    Esophagus; 2019 Oct; 16(4):377-381. PubMed ID: 31119492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Vonoprazan: a novel potassium-competitive acid blocker].
    Sugano K
    Nihon Rinsho; 2015 Jul; 73(7):1163-8. PubMed ID: 26165074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences Between Patients with Heartburn Refractory to Vonoprazan and Those Refractory to Proton Pump Inhibitors.
    Matsumura T; Sonoda M; Okimoto K; Dao HV; Takahashi S; Akizue N; Horio R; Goto C; Kurosugi A; Kaneko T; Ohta Y; Taida T; Kikuchi A; Fujie M; Kato J; Kato N
    Dig Dis Sci; 2024 Jun; 69(6):2132-2139. PubMed ID: 38622462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
    Otake K; Sakurai Y; Nishida H; Fukui H; Tagawa Y; Yamasaki H; Karashima M; Otsuka K; Inatomi N
    Adv Ther; 2016 Jul; 33(7):1140-57. PubMed ID: 27287852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis and effectiveness of pharmacist-managed outpatient clinics in Helicobacter pylori eradication therapy.
    Seko T; Tachi T; Hatakeyama H; Noguchi Y; Teramachi H
    Int J Clin Pract; 2019 Jun; 73(6):e13349. PubMed ID: 30912226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
    Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
    Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease.
    Hamada S; Ihara E; Ikeda H; Muta K; Ogino H; Chinen T; Tanaka Y; Ogawa Y
    Digestion; 2021; 102(2):197-204. PubMed ID: 31578027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of the RefluxStop device for management of refractory gastroesophageal reflux disease in Switzerland.
    Harper S; Kartha M; Mealing S; Borbély YM; Zehetner J
    J Med Econ; 2024; 27(1):805-815. PubMed ID: 38820006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
    Abe Y; Koike T; Saito M; Okata T; Nakagawa K; Hatta W; Asanuma K; Uno K; Asano N; Imatani A; Masamune A
    Digestion; 2021; 102(3):480-488. PubMed ID: 32062650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Vonoprazan for Refractory Reflux Esophagitis after Esophagectomy.
    Ochiai Y; Iizuka T; Hoshihara Y; Suzuki Y; Hayasaka J; Nomura K; Tanaka M; Odagiri H; Yamashita S; Matsui A; Kikuchi D; Ueno M; Udagawa H; Hoteya S
    Dig Dis; 2021; 39(6):569-576. PubMed ID: 33567428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
    Sakurai K; Suda H; Fujie S; Takeichi T; Okuda A; Murao T; Hasuda K; Hirano M; Ito K; Tsuruta K; Hattori M
    Dig Dis Sci; 2019 Mar; 64(3):815-822. PubMed ID: 30415407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
    Kajihara Y; Shimoyama T; Mizuki I
    Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Vonoprazan for 48-Week Maintenance Therapy of Patients with Healed Reflux Esophagitis.
    Mizuno H; Nishino M; Yamada K; Kamiyamamoto S; Hinoue Y
    Digestion; 2020; 101(4):411-421. PubMed ID: 31129668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.